Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker Commons There are currently 74 users online Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us
|
current therapiesPfizer-KineMed Collaboration Extends to Target Novel Diabetes PathwaysKineMed Inc. (www.kinemed.com) today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed’s unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|
